New founder germline mutations of CDKN2A in melanoma-prone families and multiple primary melanoma development in a patient receiving levodopa treatment

Genes Chromosomes and Cancer

Volumn 46, Issue 8, 2007, Pages 751-760

  Kannengiesser, Caroline ^a   Dalle, Stéphane ^b   Leccia, Marie Thérèse ^c   Avril, Marie Françoise ^a,d   Bonadona, Valerie ^e   Chompret, Agnès ^a   Lasset, Christine ^e   Leroux, Dominique ^c   Thomas, Luc ^b   Lesueur, Fabienne ^a   Lenoir, Gilbert ^a   Sarasin, Alain ^a   Bressac De Paillerets, Brigitte ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b HÔTEL DIEU   (France)

^c HÔPITAL MICHALLON   (France)

^d Paris Descartes University   (France)

^e CENTRE LÉON BÉRARD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CDKN2A PROTEIN; LEVODOPA; UNCLASSIFIED DRUG;

ARTICLE; CANCER RISK; CARCINOGENESIS; CDKN2A GENE; CONSANGUINITY; FRANCE; GENE LOCATION; GENE MUTATION; GENETIC MARKER; GENETIC PREDISPOSITION; GERM LINE; HAPLOTYPE; HETEROZYGOTE; HIGH RISK PATIENT; HUMAN; MELANOMA; MISSENSE MUTATION; ONCOGENE; PARKINSON DISEASE; PRIORITY JOURNAL;

DNA MUTATIONAL ANALYSIS; FAMILY; FAMILY HEALTH; FOUNDER EFFECT; FRANCE; GENE FREQUENCY; GENES, P16; GERM-LINE MUTATION; HAPLOTYPES; HUMANS; LEVODOPA; MELANOMA; PEDIGREE;

EID: 34250329627     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20461     Document Type: Article

References (53)

1. Arap W, Knudsen E, Sewell DA, Sidransky D, Wang JY, Huang HJ, Cavenee WK. 1997. Functional analysis of wild-type and malignant glioma derived CDKN2Abeta alleles: Evidence for an RB-independent growth suppressive pathway. Oncogene 15:2013-2020a.
2. 4a/CDKN2A in human glioma. Oncogene 14:603-609b.
3. Armstrong BK, English DR. 1996. Cutaneous malignant melanoma. In: Shottenfield D, Fraumeni JF Jr., editors. Cancer Epidemiology and Prevention. New York: Oxford University Press, p. 1312.
4. Auroy S, Avril MF, Chompret A, Pham D, Goldstein AM, Bianchi-Scarra G, Frebourg T, Joly P, Spatz A, Rubino C, Demenais F, Bressac-de Paillerets B. 2001. Sporadic multiple primary melanoma cases: CDKN2A germline mutations with a founder effect. Genes Chromosomes Cancer 32:195-202.
5. Begg CB, Orlow I, Hummer AJ, Armstrong BK, Kricker A, Marrett LD, Millikan RC, Gruber SB, Anton-Culver H, Zanetti R, Gallagher RP, Dwyer T, Rebbeck TR, Mitra N, Busam K, From L, Berwick M. 2005. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample. J Natl Cancer Inst 97:1507-1515.
6. Bennett DC. 2003. Human melanocyte senescence and melanoma susceptibility genes. Oncogene 22:3063-3069.
7. Bishop DT, Demenais F, Goldstein AM, Bergman W, Bishop JN, Bressac-de Paillerets B, Chompret A, Ghiorzo P, Gruis N, Hansson J, Harland M, Hayward N, Holland EA, Mann GJ, Mantelli M, Nancarrow D, Platz A, Tucker MA. 2002. Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst 94:894-903.
8. Borg A, Johansson U, Johansson O, Håkansson S, Westerdahl J, Måsbäck A, Olsson H, Ingvar C. 1996. Novel germline p16 mutation in familial melanoma in Southern Sweden. Cancer Res 56:2497-2500.
9. Box NF, Duffy DL, Chen W, Stark M, Martin NG, Sturm RA, Hayward NK. 2001. MC1R genotype modifies risk of melanoma in families segregating CDKN2A mutations. Am J Hum Genet 69:765-773.
10. Brookes S, Rowe J, Ruas M, Llanos S, Clark PA, Lomax M, James MC, Vatcheva R, Bates S, Vousden KH, Parry D, Gruis N, Smit N, Bergman W, Peters G. 2002. INK4a-deficient human diploid fibroblasts are resistant to RAS-induced senescence. EMBO J 21:2936-2945.
11. Chaudru V, Chompret A, Bressac-de Paillerets B, Spatz A, Avril MF, Demenais F. 2004. Influence of genes, nevi, and sun sensitivity on melanoma risk in a family sample unselected by family history and in melanoma-prone families. J Natl Cancer Inst 96:785-795.
12. Chaudru V, Laud K, Avril MF, Miniere A, Chompret A, Bressac-de Paillerets B, Demenais F. 2005. Melanocortin-1 receptor (MC1R) gene variants and dysplastic nevi modify penetrance of CDKN2A mutations in french melanoma-prone pedigrees. Cancer Epidemiol Biomark Prev 14:2384-2390.
13. Ciotti P, Struewing JP, Mantelli M, Chompret A, Avril MF, Santi PL, Tucker MA, Bianchi-Scarra G, Bressac-de Paillerets B, Goldstein AM. 2000. A single genetic origin for the G101W CDKN2A mutation in 20 melanoma-prone families. Am J Hum Genet 67:311-319.
14. Conrad N, Leis P, Orengo I, Medrano EE, Hayes TG, Baer S, Rosen T. 1999. Multiple primary melanoma. Dermatol Surg 25:576-581.
15. Ferrone CR, Ben Porat L, Panageas KS, Berwick M, Halpern AC, Patel A, Coit DG. 2005. Clinicopathological features of and risk factors for multiple primary melanomas. J Am Med Assoc 294:1647-1654.
16. Fiala KH, Whetteckey J, Manyam BV. 2003. Malignant melanoma and levodopa in Parkinson's disease: Causality or coincidence? Parkinsonism Relat Disord 9:321-327.
17. Fitzgerald MG, Harkin DP, Silva-Arrieta S, MacDonald DJ, Lucchina LC, Unsal H, O'Neill E, Koh J, Finkelstein DM, Isselbacher KJ, Sober AJ, Haher DA. 1996. Prevalence of germline mutations in p16, p19ARF, and CDK4 in familial melanoma: Analysis of a clinic-hased population. Proc Natl Acad Sci USA 93:8541-8545.
18. Ghiorzo P, Gargiulo S, Pastorino L, Nasti S, Cusano R, Bruno W, Gliori S, Sertoli MR, Burroni A, Savarino V, Gensini F, Sestini R, Queirolo P, Goldstein AM, Scarra GB. 2006. Impact of E27X, a novel CDKN2A germ line mutation, on p16 and p14ARF expression in Italian melanoma families displaying pancreatic cancer and neuroblastoma. Hum Mol Genet 15:2682-2689.
19. Goldstein AM, Martinez M, Tucker MA, Demenais F. 2000. Gene-covariate interaction between dysplastic nevi and the CDKN2A gene in American melanoma-prone families. Cancer Epidemiol Biomark Prev 9:889-894.
20. Goldstein AM, Liu L, Shennan MG, Hogg D, Tucker MA, Struewing JP. 2001. A common founder for the V126D CDKN2A mutation in seven North American melanoma-prone families. Br J Cancer 85:527-530.
21. Goldstein AM, Chan M, Harland M, Gillanders EM, Hayward NK, Avril MF, Azizi E, Bianchi-Scarra G, Bishop DT, Bressac-de Paillerets B, Bruno W, Calista D, Cannon Albright LA, Demenais F, Elder DE, Ghiorzo P, Gruis NA, Hansson J, Hogg D, Holland EA, Kanetsky PA, Kefford RF, Landi MT, Lang J, Leachman SA, MacKie RM, Magnusson V, Mann GJ, Niendorf K, Newton BJ, Palmer JM, Puig S, Puig-Butille JA, de Snoo FA, Stark M, Tsao H, Tucker MA, Whitaker L, Yakobson E. 2006. High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res 66:9818-9828.
22. Goldstein AM, Chan M, Harland M, Hayward NK, Demenais F, Bishop DT, Azizi E, Bergman W, Bianchi-Scarra G, Bruno W, Calista D, Cannon-Albright LA, Chaudru V, Chompret A, Cuellar F, Elder DE, Ghiorzo P, Gillanders EM, Gruis N, Hansson J, Hogg D, Holland EA, Kanetsky PA, Kefford RF, Landi MT, Lang JM, Leachman S, MacKie RM, Magnusson V, Mann G, Newton-Bishop J, Palmer JM, Puig S, Puig-Butille JA, Stark M, Tsao H, Tucker MA, Whitaker L, Yakobson E; Lund Melonoma Study Group; GenoMEL. 2007, Features associated with germline CDKN2A mutations: A GenoMEL study of melanoma-prone families from three continents. J Med Genet 44:99-106.
23. Grange F, Chompret A, Guilloud-Bataille M, Guillaume J-C, Margulis A, Prade M, Demenais F, Avril MF. 1995. Comparison between familial and nonfamilial melanoma in France. Arch Dermatol 131:1154-1159.
24. Gruis NA, Sandkuijl LA, van der Velden PA, Bergman W, Frants RR. 1995. CDKN2 explains part of the clinical phenotype in Dutch familial atypical multiple-mole melanoma (FAMMM) syndrome families. Melanoma Res 5:169-177.
25. Harland M, Mistry S, Bishop DT, Newton Bishop JA. 2001. A deep intronic mutation in CDKN2A is associated with disease in a subset of melanoma pedigrees. Hum Mol Genet 10:2679-2682.
26. Hayward NK. 2003. Genetics of melanoma predisposition. Oncogene 22:3053-3062.
27. Huot TJ, Rowe J, Harland M, Drayton S, Brookes S, Gooptu C, Purkis P, Fried M, Bataille V, Hara E, Newton-Bishop J, Peters G. 2002. Biallelic mutations in p16(INK4a) confer resistance to Ras-and Ets- induced senescence in human diploid fibroblasts. Mol Cell Biol 22:8135-8143.
28. Kennedy C, ter Huurne J, Berkhout M, Gruis N, Bastiaens M, Bergman W, Willemze R, Bavinck JN. 2001. Melanocortin 1 receptor (MC1R) gene variants are associated with an increased risk for cutaneous melanoma which is largely independent of skin type and hair color. J Investig Dermatol 117:294-300.
29. Landi MT, Goldstein AM, Tsang S, Munroe D, Modi W, Ter Minassian M, Steighner R, Dean M, Metheny N, Staats B, Agatep R, Hogg D, Calista D. 2004. Genetic susceptibility in familial melanoma from northeastern Italy. J Med Genet 41:557-566.
30. Lang J, Boxer M, MacKie RM. 2005. CDKN2A mutations in Scottish families with cutaneous melanoma: results from 32 newly identified families. Br J Dermatol 153:1121-1125.
31. Lang J, Hayward N, Goldgar D, Tsao H, Hogg D, Palmer J, Stark M, Tobias ES, MacKie R. 2007. The M53I mutation in CDKN2A is a founder mutation that predominates in melanoma patients with Scottish ancestry. Genes Chromosomes Cancer 46:277-287.
32. Laud K, Marian C, Avril MF, Barrois M, Chompret A, Goldstein AM, Tucker MA, Clark PA, Peters G, Chaudru V, Demenais F, Spatz A, Smith MW, Lenoir GM, Bressac-de Paillerets B. 2006. Comprehensive analysis of CDKN2A (p16ink4a/p14arf) and CDKN2B genes in 53 melanoma index cases considered to be at heightened risk of melanoma. J Med Genet 43:39-47.
33. Lee EY, Chang CY, Hu N, Wang YC, Lai CC, Herrup K, Lee WH, Bradley A. 1992. Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis. Nature 359:288-294.
34. Liu L, Dilworth D, Gao L, Monzon J, Summers A, Lassam N, Hogg D. 1999. Mutation of the CDKN2A5′ UTR creates an aberrant initiation codon and predisposes to melanoma. Nat Genet 21:128-132.
35. Majore S, Catricala C, Binni F, De Simone P, Eibenschutz L, Grammatico P. 2004. CDKN2A: the IVS2-105A/G intronic mutation found in an Italian patient affected by eight primary melanomas. J Investig Dermatol 122:450-451.
36. Mistry SH, Taylor C, Randerson-Moor JA, Harland M, Turner F, Barrett JH, Whitaker L, Jenkins RB, Knowles MA, Bishop JA, Bishop DT. 2005. Prevalence of 9p21 deletions in UK melanoma families. Genes Chromosomes Cancer 44:292-300.
37. Monzon J, Liu L, Brill H, Goldstein AM, Tucker MA, From L, McLaughlin J, Hogg D, Lassam NJ. 1998. CDKN2A mutations in multiple primary melanomas. N Engl J Med 338:879-887.
38. Pollock PM, Spurr N, Bishop T, Newton-Bishop J, Gruis N, van der Velden PA, Goldstein AM, Tucker MA, Foulkes WD, Barnhill R, Haber D, Fountain J, Hayward NK. 1998. Haplotype analysis of two recurrent CDKN2A mutations in 10 melanoma families: evidence for common founders and independent mutations. Hum Mutat 11:424-431.
39. Puig S, Malvehy J, Badenas C, Ruiz A, Jimenez D, Cuellar F, Azon A, Gonzalez U, Castel T, Campoy A, Herrero J, Marti R, Brunet-Vidal J, Mila M. 2005. Role of the CDKN2A locus in patients with multiple primary melanomas. J Clin Oncol 23:3043-3051.
40. Serrano M, Hannon GJ, Beach D. 1993. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366:704-707.
41. Serrano M, Lee H-W, Chin L, Cordon-Cardo C, Beach D, DePinho RA. 1996. Role of the INK4a locus in tumor suppression and cell mortality. Cell 85:27-37.
42. Sharpless NE, Bardeesy N, Lee KH, Carrasco D, Castrillon DH, Aguirre AJ, Wu EA, Horner JW, DePinho RA. 2001. Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis. Nature 413:86-91.
43. Sherr CJ, Roberts JM. 1999. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dey 13:1501-1512.
44. Siple JF, Schneider DC, Wanlass WA, Rosenblatt BK. 2000. Levodopa therapy and the risk of malignant melanoma. Ann Pharmacother 34:382-385.
45. Soufir N, Avril MF, Chompret A, Demenais F, Bombled J, Spatz A, Stoppa-Lyonnet D, the French Familial Melanoma Study Group, Bénard J, Bressac-de Paillerets B. 1998. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. Hum Mol Genet 7:209-216.
46. Sturm RA. 2002. Skin colour and skin cancer - MC1R, the genetic link. Melanoma Res 12:405-416.
47. Takahashi A, Ohtani N, Yamakoshi K, Iida S, Tahara H, Nakayama K, Nakayama KI, Ide T, Saya H, Hara E. 2006. Mitogenic signalling and the p16INK4a-Rb pathway cooperate to enforce irreversible cellular senescence. Nat Cell Biol 8:1291-1297.
48. van der Velden PA, Sandkuijl LA, Bergman W, Pavel S, van Mourik L, Frants RR, Gruis NA. 2001. Melanocortin-1 receptor variant R151C modifies melanoma risk in Dutch families with melanoma. Am J Hum Genet 69:774-779.
49. Weber JD, Taylor LJ, Roussel MF, Sherr CJ, Bar-Sagi D. 1999. Nucleolar Arf sequesters Mdm2 and activates p53. Nat Cell Biol 1:20-26.
50. Yakobson E, Eisenberg S, Isacson R, Halle D, Levy-Lahad E, Catane R, Safro M, Sobolev V, Huot T, Peters G, Ruiz A, Malvehy J, Puig S, Chompret A, Avril MF, Shafir R, Peretz H, Bressac-de Paillerets B. 2003. A single Mediterranean, possibly Jewish, origin for the Val59Gly CDKN2A mutation in four melanoma-prone families. Eur J Hum Genet 11:288-296.
51. Zanetti R, Loria D, Rosso S. 2006. Melanoma, Parkinson's disease and levodopa: causal or spurious link? A review of the literature. Melanoma Res 16:201-206.
52. Zhang Y, Xiong Y, Yarbrough WG. 1998. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92:725-734.
53. Zhang J, Schweers B, Dyer MA. 2004. The first knockout mouse model of retinoblastoma. Cell Cycle 3:952-959.